Abstracts tagged "autoantibodies and rheumatoid arthritis (RA)"

Abstract Number: 14 • 2018 ACR/ARHP Annual Meeting
Individual RA-Derived Monoclonal Anti-Citrullinated Protein Autoantibodies (ACPA) Have Extensive Citrulline Multi-Reactivity Demonstrated By a Large-Scale Protein Array Platform
Peter Sahlström¹, Johanna Steen¹, Madeleine Jenning², Philip J. Titcombe^1,3, Ute Nonhoff^4,5, Ragnhild Stålesen⁶, Bianka Marklein², Daniel L. Mueller³, Zoltan Konthur⁴, Karin Lundberg⁷, Anca I. Catrina⁶, Lars Klareskog¹, Vivianne Malmström¹, Karl Skriner² and Caroline Grönwall⁸, ¹Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Dept. of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Engine GmbH, Hennigsdorf, Germany, ⁵Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, ⁶Rheumatology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The presence of serum IgG anti-citrullinated protein autoantibodies (ACPA) in rheumatoid arthritis (RA), is associated with more aggressive disease progression. Although ACPA have been…
Abstract Number: 77 • 2018 ACR/ARHP Annual Meeting
Single Nucleotide Polymorphism in the Gene Encoding Peptidylarginine Deiminase 4 Correlates with Reduced Neutrophil Extracellular Traps and Anti-Histone Antibodies in Rheumatoid Arthritis
Aisha M. Mergaert¹, Mandar Bawadekar², Thai Q. Nguyen¹, Steven J. Schrodi^3,4 and Miriam A. Shelef^2,5, ¹University of Wisconsin - Madison, Madison, WI, ²Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, ³Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI, ⁴Computation and Informatics in Biology and Medicine, University of Wisconsin - Madison, Madison, WI, ⁵William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: In neutrophils, peptidylarginine deiminase 4 (PAD4) citrullinates histones allowing chromatin unraveling and neutrophil extracellular trap (NET) formation. NETs are increased and display proteins targeted…
Abstract Number: 79 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA)-Associated Autoantibodies Are Present in the Periodontal Exudate of Patients with and without RA
Poerwati Soetji Rahajoe¹, Menke J. de Smit², Elisabeth Eelsing², Nyoman Kertia³, Arjan Vissink⁴ and Johanna Westra², ¹Oral Surgery, Dr. Sardjito General Hospital, Yogyakarta, Indonesia, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology, Dr. Sardjito General Hospital, Yogyakarta, Indonesia, ⁴Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Seropositivity for anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) is a hallmark of RA and can be present years before clinical onset has…
Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
Yuki Ishikawa¹, Motomu Hashimoto², Hiromu Ito³, Masao Tanaka², Naoichiro Yukawa⁴, Takao Fujii⁵, Wataru Yamamoto⁶, Tsuneyo Mimori⁷ and Chikashi Terao^8,9,10, ¹One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Wakayama University, Wakayama, Japan, ⁵Dept of Rheum/Clinical Immun, Wakayama Medical University, Wakayama, Japan, ⁶Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Center for Investigative Medical Sciences, RIKEN, Yokohama, Japan, ⁹Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ¹⁰Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…
Abstract Number: 1441 • 2018 ACR/ARHP Annual Meeting
Diagnostic Performances of Antibodies Against Carbamylated Proteins in US Based Populations with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
Jing Shi¹, Jay Milo², Kelley Bradey¹, Chelsea Bentow², John Conklin¹, Tyler O'Malley¹, Armida Sace¹, Rowena Lafon¹, Duncan Poling¹, Claudia Ibarra¹, Michael Mahler² and Thierry Dervieux¹, ¹Exagen Diagnostics, Inc., Vista, CA, ²Research and Development, Inova Diagnostics, San Diego, CA
Background/Purpose: Recently, antibodies directed against carbamylated antigens (anti-CarP antibodies) were identified in rheumatoid arthritis (RA). Studies have established the predictive and prognostic value of this…
Abstract Number: 393 • 2017 ACR/ARHP Annual Meeting
The Role of Follicular Helper 17 T Cells in Glucose-6-Phosphate Isomerase Induced Arthritis
Izumi Kurata, Isao Matsumoto, Atsumu Osada, Hiroshi Ebe, Hoshimi Kawaguchi, Yuya Kondo, Hiroto Tsuboi and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Follicular helper T (Tfh) cell is a novel T cell subset which promotes follicular B cell activation, differentiation to plasma cell and antibody production.…
Abstract Number: 1363 • 2017 ACR/ARHP Annual Meeting
Disease Duration and Shared Epitope, but Not Smoking History, Are Associated with Peptidylarginine Deiminase 4-Antibody Development in Rheumatoid Arthritis
Laura Cappelli¹, Maximilian Konig¹, Pooja Naik², Arvin Saleh³, Allan C. Gelber³, Clifton O. Bingham III⁴ and Erika Darrah⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine/Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Clinical characteristics and biomarkers help clinicians predict disease features in rheumatoid arthritis (RA). Both peptidylarginine deiminase 4 (PAD4) antibodies and smoking have been associated…
Abstract Number: 1402 • 2017 ACR/ARHP Annual Meeting
In RA, Becoming Seronegative over the 1st Year of DMARD Treatment Does Not Improve Chances of Drug-Free Remission in the Long-Term
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², Yvonne P. Goekoop-Ruiterman³, GM Steup-Beekman^1,4, Tom W.J. Huizinga⁵, Cornelia F Allaart⁵, Rene E.M. Toes¹ and Diane van der Woude⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients with RA harbor autoantibodies of various isotypes and directed against several post-translational modifications. Baseline seropositivity is a poor prognostic factor for sustained drug-free…
Abstract Number: 1971 • 2017 ACR/ARHP Annual Meeting
Association between Genetic Variants and the Presence of Rheumatoid Arthritis-Related Autoimmunity and Progression to Classified Rheumatoid Arthritis in an at-Risk Population
Rachael Sawaya¹, Elizabeth A. Bemis¹, Ryan W. Gan², Jill M. Norris³, Jeffrey A. Sparks⁴, Elizabeth Karlson⁵, M. Kristen Demoruelle⁶, Kevin D. Deane⁷, V. Michael Holers⁸, Marie L. Feser⁷, Laurie Moss⁷, Jane H. Buckner⁹, Richard M. Keating¹⁰, Peter Gregersen¹¹, Michael Weisman¹², Ted R. Mikuls¹³ and James R. O'Dell¹⁴, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Colorado School of Public Health, University of Colorado Denver, Aurora, CO, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶1775 Aurora Ct, 1775 Aurora Ct, Aurora, CO, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁸Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰Division of Rheumatology, Scripps Clinic, La Jolla, CA, ¹¹The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ¹²Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ¹³Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ¹⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by the presence of RA-related autoantibodies prior to the development of clinical disease. While HLA-shared epitope…
Abstract Number: 2916 • 2017 ACR/ARHP Annual Meeting
The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², R.J. Goekoop³, I Speyer⁴, TWJ Huizinga¹, CF Allaart¹, REM Toes¹ and Diane van der Woude⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Haga Hospital, The Hague, Netherlands, ⁴Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The autoantibody response of seropositive RA is very diverse and consists of various numbers of isotypes and antibodies to multiple post-translational modifications. It is…
Abstract Number: 2113 • 2016 ACR/ARHP Annual Meeting
Anti-Carbamylated Protein Antibody (cross)-Reactivity Against Multiple Carbamylated Protein Antigens
Marije K. Verheul¹, Myrthe van Delft², Tom WJ Huizinga¹, REM Toes¹ and LA Trouw¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Antibodies that target carbamylated proteins (anti-CarP) have been implicated in rheumatoid arthritis and are known to associate with joint damage. Furthermore, these autoantibodies…
Abstract Number: 550 • 2015 ACR/ARHP Annual Meeting
Can Anti-TNF-Induced Autoantibody Conversion be Reversed By Switching to Abatacept Therapy in Patients with RA on Background MTX?
Maya H. Buch¹, A Johnsen², DA Wong² and M Schiff³, ¹University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²Bristol-Myers Squibb, Princeton, NJ, ³University of Colorado, Denver, CO
Background/Purpose: Anti-TNF therapy for RA is associated with antinuclear (ANAs) and anti-double-stranded DNA (anti-dsDNA) autoantibodies.1,2 The effect of biologics on autoantibody-positive patients is unknown. We…
Abstract Number: 578 • 2015 ACR/ARHP Annual Meeting
Study of the Production of Antinuclear Antibodies and Anti-Ds DNA Antibodies in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Ran Matsudaira^1,2, Naoto Tamura³, Yoshichika Sugisaki², Tomoko Ito⁴, Kentaro Minowa², Michihiro Ogasawara², Ken Yamaji², Yoshinori Kanai¹, Kenjiro Yamanaka¹ and Yoshinari Takasaki², ¹Division of Internal Medicine and Rheumatology, Sasaki institute Kyoundo Hospital, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University, School of Medicine, Tokyo, Japan, ³Department of Internal Medicien and Rheumatology, Juntendo University, School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: The production of autoantibodies, such as anti-nuclear antibodies (ANA) and anti-ds DNA antibodies (anti-DNA), is commonly observed in patients who have been treated with…
Abstract Number: 1212 • 2015 ACR/ARHP Annual Meeting
Investigation of Vitamin D Supplement Use, Rheumatoid Arthritis-Related Autoimmunity and Joint Signs Among Those at Increased Risk for the Development of Rheumatoid Arthritis
Elizabeth A. Bemis¹, Ryan W. Gan², Marie L. Feser³, Michael H. Weisman⁴, James R. O'Dell⁵, Ted R. Mikuls⁵, Jane H. Buckner⁶, Peter K. Gregersen⁷, Richard M. Keating⁸, M. Kristen Demoruelle⁹, Kevin D. Deane¹⁰, V. Michael Holers¹¹ and Jill M. Norris¹², ¹Epidemiology, Epidemiology, Colorado School of Public Health, Aurora, CO, ²Colorado School of Public Health, University of Colorado Denver, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Feinstein Insititute for Medical Research, Manhasset, NY, ⁸Division of Rheumatology, Scripps Health, La Jolla, CA, ⁹Rheumatology, University of Colorado School of Medicine, Aurora, CO, ¹⁰Division of Rheumatology, U Colo Denver, Aurora, CO, ¹¹Rheumatology Division, Univ of Colorado School of Med, Aurora, CO, ¹²University of Colorado Denver, Aurora, CO
Background/Purpose: Vitamin D has immunomodulatory properties, and could be a protective factor against rheumatoid arthritis (RA). Anti-cyclic citrullinated peptide (anti-CCP) autoantibodies and swollen small joints…
Abstract Number: 1511 • 2015 ACR/ARHP Annual Meeting
Increased Prevalence of Anti-Nuclear and Anti-SSA Autoantibodies in African American Rheumatoid Arthritis Patients Versus Matched Caucasian Rheumatoid Arthritis Patients
Tyler Sevco¹, Douglas P. Landsittel², Chengli Shen³, Bruce Rabin⁴ and Larry W. Moreland⁵, ¹Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: African American (AA) patients with rheumatoid arthritis (RA) have worse Health Assessment Questionnaire (HAQ) scores and increased disease activity clinically compared to Caucasian (CAU)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].